Overview

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

Status:
Recruiting
Trial end date:
2022-07-15
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Phase:
Phase 2
Details
Lead Sponsor:
Gary Morrow
University of Rochester NCORP Research Base
Collaborator:
National Cancer Institute (NCI)
Treatments:
Ibuprofen